New drug shows promise for eye disease that blinds millions
NCT ID NCT07547228
First seen Apr 25, 2026 · Last updated May 17, 2026 · Updated 3 times
Summary
This study tests a new drug called PRL3-zumab for people with a severe form of age-related vision loss (wet AMD) that hasn't responded to standard treatments. About 15 participants will receive either a low dose, high dose, or placebo through an IV every two weeks for three doses. The goal is to see if the drug is safe and can improve or stabilize vision over 24 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOVASCULAR AGE RELATED MACULAR DEGENERATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
NUHS Department of Ophthalmology
RECRUITINGSingapore, Singapore
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.